Considered all together, these findings suggest TRPV4 as an attractive target in atherosclerosis and other diseases, thus incentivizing the discovery of small molecule inhibitors of TRPV4 that can be translated into clinically effective therapeutics. This evidence concerns the gene TRPV4 and atherosclerosis.